The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension

Citation
Jm. Neutel et al., The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension, INT J CL PR, 53(3), 1999, pp. 175-178
Citations number
17
Categorie Soggetti
General & Internal Medicine
Journal title
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
ISSN journal
13685031 → ACNP
Volume
53
Issue
3
Year of publication
1999
Pages
175 - 178
Database
ISI
SICI code
1368-5031(199904/05)53:3<175:TEASOT>2.0.ZU;2-4
Abstract
This 8-week, open-label study compared the efficacy and safety of once-dail y telmisartan, either alone or in combination with hydrochlorothiazide (HCT Z) and amlodipine, with a similar enalapril regimen in patients with severe hypertension. Clinically relevant reductions in supine systolic blood pres sure/DBP were observed with telmisartan (14.6/13.2 mmHg) and enalapril (13. 0/12.9 mmHg) monotherapy. Incremental reductions were seen with up-titratio n of monotherapy (telmisartan 8.1/7.4 and enalapril 9.2/7.7 mmHg), and the addition of HCTZ (telmisartan 14.9/8.7 and enalapril 8.0/6.7 mmHg), and aml odipine (telmisartan 8.0/6.5 and enalapril 10.5/6.4). After 8 weeks of trea tment, supine DBP control was achieved in 55% and 35% of the patients on th e telmisartan and enalapril regimens, respectively. Both treatment regimens were well tolerated. Telmisartan, a new angiotensin receptor blocker, is a safe and effective drug to use in combination for the treatment of patient s with severe hypertension and proved at least as effective as the enalapri l combination.